What is BioMarin Pharmaceuticals's free cash flow?

BioMarin Pharmaceuticals (BMRN) reported free cash flow of $199.73M in Q1 2026.

How has BioMarin Pharmaceuticals's free cash flow changed year-over-year?

BioMarin Pharmaceuticals's free cash flow increased by 26.7% year-over-year, from $157.63M to $199.73M.

What is the long-term trend for BioMarin Pharmaceuticals's free cash flow?

Over 2 years (2021 to 2025), BioMarin Pharmaceuticals's free cash flow has grown at a 78.9% compound annual growth rate (CAGR), from $226.52M to $724.96M.

BioMarin Pharmaceuticals BMRN Free cash flow

Free cash flow at other companies

BiogenBIIB

$594.3M+167%

BridgeBio PharmaBBIO

——

Krystal Biotech, Inc.KRYS

——

Neurocrine BiosciencesNBIX

——

Globus MedicalGMED

——

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Valuation

See full

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Profitability

See full

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Where this comes from

Calculated from BioMarin Pharmaceuticals’s reported figures.

$220.7Mnet cash from operating−$20.9Mcapital expenditures=$199.73M

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's free cash flow?: BioMarin Pharmaceuticals (BMRN) reported free cash flow of $199.73M in Q1 2026.
How has BioMarin Pharmaceuticals's free cash flow changed year-over-year?: BioMarin Pharmaceuticals's free cash flow increased by 26.7% year-over-year, from $157.63M to $199.73M.
What is the long-term trend for BioMarin Pharmaceuticals's free cash flow?: Over 2 years (2021 to 2025), BioMarin Pharmaceuticals's free cash flow has grown at a 78.9% compound annual growth rate (CAGR), from $226.52M to $724.96M.